knowledge -WSS

knowledge

author：Wikipedia 2025-10-02 00:28:40 - browse：4621

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Feed a cold, starve a fever? Here’s what science says

hotspot

WSS

Flash flood warnings continue for parts of Missouri, Illinois

With heat waves through August, officials warn of health risks

Congress needs to close a vaccine

STAT wants to know your pick for a great summer read or listen

FTC loses bid to block Novant's North Carolina hospital merger

Sweden knocks USA out of World Cup in penalty kicks

hotspot

knowledge

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Finland to offer bird flu vaccine to select groups of people, a possible global first

Tori Bowie and the unacceptable rates of Black maternal death

The most pressing bird flu mysteries scientists want answered

After affirmative action ruling, medical educators look to 'holistic review'

For pregnant people, addiction treatment shouldn't mean a call to child protective services

United colonoscopy coverage change 'may cost lives,' doctors say

Structure Therapeutics oral GLP

Supreme Court strikes down use of affirmative action

How CRISPR works, explained in two minutes

explore

FTC loses bid to block Novant's North Carolina hospital merger

Sutter Health’s antitrust win overturned by appeals court

Feed a cold, starve a fever? Here’s what science says

FDA approves Moderna’s RSV vaccine, its second licensed product

Trump used to be more articulate. What could explain the change?

Elevance PBM president out as customers face prescription chaos

entertainment

focus

hotspot

leisure time